STERIS (NYSE:STE) Issues FY 2027 Earnings Guidance

STERIS (NYSE:STE) issued an update on its FY 2027 earnings guidance on Monday morning. The company provided earnings per share guidance of 11.100-11.300 for the period, compared to the consensus earnings per share estimate of 11.070. The company issued revenue guidance of $6.4 billion-$6.4 billion, compared to the consensus revenue estimate of $6.3 billion.

STERIS Trading Down 2.7%

Shares of STE stock opened at $201.95 on Tuesday. STERIS has a fifty-two week low of $195.14 and a fifty-two week high of $269.44. The company has a 50 day moving average price of $222.37 and a 200 day moving average price of $243.74. The stock has a market capitalization of $19.81 billion, a P/E ratio of 28.17 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48.

STERIS (NYSE:STE) last issued its quarterly earnings results on Monday, May 11th. The medical equipment provider reported $2.83 EPS for the quarter, missing the consensus estimate of $2.86 by ($0.03). STERIS had a net margin of 12.15% and a return on equity of 14.34%. The business had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.59 billion. During the same period in the prior year, the business earned $2.74 EPS. The business’s quarterly revenue was up 6.7% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Equities research analysts predict that STERIS will post 10.22 EPS for the current fiscal year.

STERIS Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 26th. Stockholders of record on Monday, June 8th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Monday, June 8th. STERIS’s dividend payout ratio (DPR) is presently 35.15%.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Weiss Ratings cut shares of STERIS from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, April 16th. Wall Street Zen downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Sunday, April 26th. Five equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, STERIS has a consensus rating of “Moderate Buy” and an average price target of $275.20.

Insider Activity

In other news, Director Cynthia L. Feldmann sold 3,098 shares of the business’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $237.21, for a total value of $734,876.58. Following the completion of the sale, the director directly owned 705 shares of the company’s stock, valued at approximately $167,233.05. The trade was a 81.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.07% of the company’s stock.

Key Stories Impacting STERIS

Here are the key news stories impacting STERIS this week:

• Positive Sentiment: STERIS raised fiscal 2027 EPS guidance to $11.10-$11.30, topping analyst expectations and signaling confidence in continued demand. Reuters article
• Positive Sentiment: Revenue rose 6.7% year over year in the quarter, and operating profit and net income improved meaningfully, showing the core business is still expanding. GlobeNewswire article
• Neutral Sentiment: The company’s results were broadly close to expectations, with only a small EPS and revenue miss, so investors may see the quarter as mixed rather than weak. Zacks article
• Negative Sentiment: The stock is under pressure because the quarter technically missed consensus EPS and revenue estimates, which can prompt profit-taking after the recent run. Quiver Quantitative article

Institutional Trading of STERIS

A number of large investors have recently bought and sold shares of the business. AQR Capital Management LLC raised its holdings in shares of STERIS by 178.6% in the third quarter. AQR Capital Management LLC now owns 1,183,070 shares of the medical equipment provider’s stock valued at $291,704,000 after buying an additional 758,423 shares during the last quarter. Boston Partners purchased a new stake in STERIS during the 3rd quarter valued at approximately $158,982,000. Orbis Allan Gray Ltd grew its stake in shares of STERIS by 36.0% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock valued at $504,486,000 after purchasing an additional 556,088 shares during the last quarter. State Street Corp increased its holdings in shares of STERIS by 6.0% in the fourth quarter. State Street Corp now owns 4,614,840 shares of the medical equipment provider’s stock valued at $1,169,957,000 after purchasing an additional 260,001 shares during the period. Finally, Alliancebernstein L.P. raised its stake in shares of STERIS by 101.9% during the third quarter. Alliancebernstein L.P. now owns 418,359 shares of the medical equipment provider’s stock worth $103,519,000 after purchasing an additional 211,107 shares during the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.